Sanuwave Health inks dev deal with eKare for wound care integration

Sanuwave Health (OTC:SNWV) said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies. Through the deal, Sanuwave’s dermaPace wound treatment device will be linked with eKare’s inSight 3D wound imaging and analytics system to produce a comprehensive wound management solution, Suwanee, Ga.-based Sanuwave said. “We are excited to be teaming with Sanuwave to elevate inSight’s strength in imaging and analytics to develop better treatment algorithms for the dermaPace solution. This potent combination of therapy, 3D imaging, and data analytics can pave the path to powerful and cost effective wound closure solutions,” eKare CCO Travis Smith said in a prepared statement. Venezuala-based eKare’s inSight device is designed to use computer vision and 3D sensing technology to assess healing progress of wounds and feed that data into an AI analytics engine to produce actionable data, the company said. The device has both FDA 510(k) clearance in the US and CE Mark approval in the European Union. Sanuwave’s dermaPace has CE Mark approval in the European Union, and is licensed for use in Canada, Australia and South Korea and is designed to treat skin conditions, specifically diabetic foot ulcers and venous leg ulcers. “Having conducted and analyzed two highly controlled wound studies, we have recognized that successful wound closur...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Research & Development Wound Care ekare SANUWAVE Health Inc. Source Type: news